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ABSTRACT
Breakthrough pain is a transient exacerbation of
pain that occurs either spontaneously, or in
relation to a specific predictable or unpredictable
trigger, despite relatively stable and adequately
controlled background pain. Typically,
breakthrough pain has a fast onset and short
duration, and a significant impact on patients’
quality of life. Normal-release oral opioids are
the traditional pharmacological approach for
patients who are receiving an around the clock
opioid regimen; however, their onset and
duration of action may not be suitable for
treating many breakthrough pains. Efforts to
provide nonparenteral opioid formulations that
could provide more rapid, and more effective,
relief of breakthrough pain have led to the
development of transmucosal opioid
formulations including fentanyl sublingual
spray (FSLS). This is a formulation of fentanyl
available in doses of 100, 200, 400, 600, and
800 lg strengths approved for the management
of breakthrough pain in adult cancer patients
already receiving and who are tolerant to opioid
therapy for their underlying persistent cancer
pain. Published pharmacokinetic, efficacy,
tolerability, and safety data suggest that FSLS
has a valuable role to play in the symptomatic
pharmacological management of breakthrough
pain. The effective dose of FSLS is determined by
titration according to the needs of the individual
patient.
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INTRODUCTION
Most patients with advanced cancer experience
some degree of persistent background pain, the
prevalence of which increases with disease
progression, with rates of 30–40% during early
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disease, rising to 70–90% in advanced disease
[1]. As pain assessment methods have evolved it
has become increasingly clear that patients with
cancer often report variations in their pain
during the course of the day. Moreover,
between 20% and 95% of patients also
experience transitory exacerbation of pain,
known as breakthrough pain [2]; the incidence
varying according to the population surveyed
and the definition of breakthrough pain used
[2]. Breakthrough pain is associated with a
significant negative impact on quality of life,
yet surveys suggest that patients are not being
treated optimally [3, 4]. In recent years a number
of products specifically developed for the
management of breakthrough pain have
become available, most of which deliver
fentanyl transmucosally. The aim of this paper
is to review sublingual fentanyl spray, which is
one of the most recent additions; other products
have already been reviewed elsewhere [5, 6].
Definitions
Breakthrough pain is a transient exacerbation of
pain that occurs either spontaneously, or in
relation to a specific predictable or
unpredictable trigger, despite relatively stable
and adequately controlled background pain [7].
First described by Portenoy and Hagen in 1990
[8], the term has been used to describe a
phenomenon whereby pain intensity suddenly
increases to ‘‘break through’’ the background
pain that is otherwise controlled by around the
clock (ATC) medication.
Breakthrough pain has been variably defined
in the literature. Some authors have proposed
that breakthrough pain exists only when
background pain is controlled [8]; others have
suggested breakthrough pain may exist in
patients with uncontrolled background pain
and irrespective of analgesic regimen [4, 9].
These differences have led to difficulties
comparing studies.
Given the importance of distinguishing
breakthrough pain from uncontrolled
background pain, it has been suggested that
three questions would be helpful to distinguish
between the two [7]:
• Does the patient have background pain?
• Is the background pain adequately
controlled?
• Does the patient have transient exacerbations
of pain?
Characteristics
Breakthrough pain is heterogeneous and
prevalent at all stages of disease, but appears
most common in patients with advanced
disease and poor performance status [4]. The
characteristics of breakthrough pain vary from
individual to individual, and may vary within
an individual over time. Typically, the etiology
and pathophysiology of the breakthrough pain
are related to the background pain and the
episodes are severe or excruciating in intensity,
have a rapid onset (3–5 min to peak intensity),
last for 15–30 min, and occur, on average, four
times a day [8, 10–12].
Two subtypes of breakthrough pain have
been described. First, incident pain, reported in
32–94% of patients [13, 14], may be predictable
when precipitated by volitional factors (e.g.,
movement) or unpredictable when precipitated
by non-volitional factors (e.g., bladder spasm).
Incident pain has been shown to be a poor
predictor of successful pharmacological therapy
[14, 15]. Second, spontaneous pain, which has
been reported in 28–45% of patients [8, 13], and
occurs in the absence of a specific trigger.
Spontaneous pain can occur randomly and
unpredictably with little or no warning,
making management difficult.
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Some patients report pain that consistently
occurs just before the next scheduled dose of
ATC analgesia, so-called ‘‘end-of-dose’’ pain.
This occurs either because the ATC analgesic
dose is inadequate, or because the interval
between administrations is too long. Although
‘‘end-of-dose’’ pain is sometimes included in the
classification of breakthrough pain, it does not
fit the definition given above, as background
pain is not controlled.
Impact
Breakthrough pain has been shown to have
significant physical, psychological, and
economic burdens on both patients and their
carers. Breakthrough pain is associated with
decreased patient satisfaction [10, 12],
decreased functioning, anxiety, and depression
[10]. Furthermore, breakthrough pain can be a
poor prognostic indicator [14, 16, 17], and can
place additional burdens on the healthcare
system (e.g., increases in emergency and
medical visits, more hospital admissions, and
longer stays) [18], and on patients with
increased direct costs (e.g., prescriptions) and
indirect costs (e.g., child care) [19].
Breakthrough pain is therefore a significant
clinical challenge, and patients require fast and
effective treatment to control the pain, improve
quality of life, and increase their independence.
The most common pharmacological
management is with supplemental doses of
oral opioids also known as ‘‘rescue
medication.’’ A rapid onset of action and short
duration of effect are among the key
characteristics of an ideal rescue medication.
The most appropriate route of administration
for a rescue medication is dependent on the
nature of the pain and the clinical profile of the
patient and, at any given time, a patient with
cancer may receive several pain medications
using different administration routes to provide
optimal analgesia. Although oral drug
administration is usually preferred because it is
convenient and usually inexpensive, the
pharmacokinetic and pharmacodynamic
profiles of many drugs delivered orally do not
mirror closely the characteristics of
breakthrough pain, resulting in only partially
effective treatment and/or troublesome adverse
effects [11]. In an effort to deliver more effective
treatment of breakthrough pain ways of
improving drug absorption have been explored.
Transmucosal Opioids
The recognized mismatch between the
pharmacodynamics of oral and parenteral
opioids and the typical time course of an
episode of breakthrough pain, together with
the inconvenience of parenteral administration,
has led to a search for alternative drugs and
drug delivery systems to improve the
management of breakthrough pain. In this
respect, opioid formulations that utilize the
oral transmucosal (buccal and sublingual) and
intranasal routes have emerged as effective
options for the management of breakthrough
pain [20].
These routes of administration also have the
advantage that they utilize a highly vascular
area, allowing rapid drug absorption, and
circumvent or reduce absorption from the
gastrointestinal tract, a particular advantage
for patients who have difficulty swallowing or
have a damaged or impaired gastrointestinal
tract [21]. In addition, first-pass metabolism by
the liver is avoided or reduced, which increases
the proportion of the dose entering the systemic
circulation, thereby allowing the amount of
drug ingested to be minimized.
Pain Ther (2013) 2:1–9 3
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Sublingual Transmucosal Delivery
The oral mucosa is an attractive route for drug
delivery as it is generally associated with more
rapid absorption compared with the oral route.
Fentanyl is a highly lipophilic opioid and, when
placed in saliva under normal oral conditions,
80% of the administered dose remains
nonionised allowing the drug to pass readily
through the buccal mucosa, quickly cross the
blood–brain barrier and enter the central
nervous system [22].
The buccal and sublingual tissues are the
primary focus for drug delivery via the oral
mucosa because they are more permeable than
the tissues in the other area of the mouth. The
mucosa is easily accessible, convenient,
noninvasive, and less threatening to patients
compared to other routes of administration
such as intravenous or intramuscular.
Furthermore, it does not require technical
equipment, expertise, preparation and
supervision. The buccal mucosa is highly
vascularized and therefore any drugs diffusing
into the oral mucosa membranes have direct
access to the systemic circulation via capillaries
and venous drainage. Drugs are absorbed
through the oral mucosa directly into the
systemic circulation [21].
METHODS
A Medline search was performed to identify the
relevant literature. The search terms used
included ‘‘breakthrough pain,’’ ‘‘incident pain,’’
and ‘‘episodic pain,’’ ‘‘sublingual,’’ and
‘‘fentanyl,’’ the database was searched up until
November 2012, and limits used were human
and English language. Additional papers were
sought from the reference lists of the retrieved
papers. The search identified one pivotal study.
Further information was obtained from the US
Food and Drug Administration website. Insys
Pharmaceutical Inc. was contacted for
additional information but none was received.
Fentanyl Sublingual Spray
Fentanyl sublingual spray (FSLS) is a
sublingually administered formulation of
fentanyl available in doses of 100, 200, 400,
600, and 800 lg strengths approved in the USA
for the management of breakthrough pain in
adult cancer patients already receiving and who
are tolerant to opioid therapy for their
underlying persistent cancer pain. Patients
considered opioid tolerant are those who are
taking ATC medicine consisting of at least
60 mg of oral morphine daily, at least 25 lg/h
of transdermal fentanyl, at least 30 mg of oral
oxycodone daily, at least 8 mg of oral
hydromorphone daily, or an equianalgesic
dose of another opioid daily for a week or
longer.
Pharmacokinetics
Following the single dose administration of
FSLS 400 lg, the mean absolute bioavailability
of fentanyl compared to fentanyl citrate 100 lg
intravenous injection was 76% as measured by
AUC0–? and normalized for dose [23]. In an
open-label study that compared the relative
bioavailability of FSLS and oral transmucosal
fentanyl citrate (OTFC) in 21 healthy adult
subjects, the rate and extent of fentanyl
absorption were considerably greater with FSLS
(34% greater maximum plasma concentration
[Cmax = 0.81 ng/mL for FSLS vs. 0.61 ng/mL for
OTFC] and 36% greater systemic exposure
[AUC0-? = 5.76 ng/mL/h for FSLS vs. 4.18 ng/
mL/h for OTFC]) [22].
Dose proportionality of 100, 200, 400,
600, and 800 lg strengths of FSLS has been
evaluated in a crossover study in healthy
subjects [23]. Both the Cmax (0.20, 0.38, 0.80,
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1.17, and 1.61 ng/mL, respectively) and
AUC0-? (1.25, 2.48, 5.34, 7.45, and 10.38
ng/mL/h, respectively) values increased in a
dose-dependent manner that was
approximately proportional to the FSLS doses
administered [23].
The effect of Grades 1 and 2 mucositis on the
pharmacokinetics of FSLS was studied in a
group of cancer patients with mucositis (n = 7
for Grade 1 and n = 2 for Grade 2) and without
mucositis (n = 8). A single 100 lg dose was
administered. Cancer patients with Grade 1
mucositis compared to patients without
mucositis exhibited 73% greater Cmax (0.45 vs.
0.26 ng/mL) and 52% greater AUClast (1.38 vs.
0.91 ng/mL/h) values. The two cancer patients
with Grade 2 mucositis had four and sevenfold
higher Cmax and more than threefold higher
AUClast values compared to patients without
mucositis [23].
Efficacy
The efficacy of FSLS was investigated in a
double-blind, placebo-controlled, crossover
study in opioid-tolerant adults with cancer
and breakthrough pain [24]. Patients received
FSLS from 100 lg per dose to 1,600 lg per dose.
The study began with an open-label dose
titration period followed by a double-blind
treatment period. The goal of titration was to
find the dose of FSLS that provided adequate
analgesia with acceptable side effects. Once a
successful dose was established, patients were
enrolled into the double-blind period and
randomly assigned to a sequence of 10
treatments; seven with FSLS and three with
placebo. The subjects assessed pain intensity on
a 100 mm visual analog scale that rated the pain
as 0 = none to 100 = worst possible pain. With
each episode of breakthrough pain, pain
intensity was assessed first and then treatment
was administered. Pain intensity (0–100) was
then measured at 5, 10, 15, 30, 45, and 60 min
after the start of administration. The primary
endpoint was the summed pain intensity
difference from baseline to 30 min after dosing
(SPID30).
Out of 130 patients who entered the titration
phase, 98 (75%) were able to titrate to a dose of
FSLS that adequately reduced pain with
tolerable side effects and entered into the
double-blind period; 79 patients completed all
10 doses of blinded study drug [24]. The median
effective dose was 800 lg, and 58.2% of patients
attained an effective dose between 800 and
1,600 lg. Comparison of FSLS and placebo
showed that FSLS was statistically superior in
reducing pain intensity using the primary
outcome SPID30 (Fig. 1). Furthermore,
secondary efficacy analyses including total
pain relief and patient global evaluation of
study medication at 30 min also favored FSLS.
Moreover, rescue medication was used by
patients during 28% of episodes treated by
placebo compared to 10% of episodes treated
with FSLS.
Fig. 1 Mean summed pain intensity difference ± SE for
fentanyl sublingual spray (FSLS) and placebo at each time
point [23]
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Safety and Tolerability
The safety of FSLS has been evaluated in a total
of 359 patients including patients from the
efficacy study and patients from an open-label
safety study lasting up to 90 days that rolled
patients over from the efficacy study and
enrolled new patients [23]. During the efficacy
study the most commonly reported adverse
effects during titration were nausea (13%),
somnolence (8.5%), dizziness (7.7%), and
vomiting (7.7%), and during the efficacy phase
nausea (7.1%), hyperhidrosis (5.1%), and
peripheral edema (5.1%); the majority mild or
moderate in intensity. Application site irritation
occurred in three patients (2.3%) during the
titration period; this adverse event led to study
discontinuation in one patient.
Safety data from a long-term extension study
showed that the average duration of therapy in
the open-label study was 66 days [23]. The
maximum duration of therapy was 149 days.
The dose range studied in these trials ranged
from 100 lg per dose to 1,600 lg per dose. The
most commonly observed adverse reactions
seen with FSLS are typical opioid side effects
such as nausea, vomiting, somnolence, and
constipation. The most common adverse
reaction leading to discontinuation of FSLS
was nausea.
The risk of respiratory depression is often
associated with opioids and usually considered
more likely with the short-acting formulations,
although in clinical practice provided the drug
is used in accordance with the label, respiratory
depression is seldom a problem. Moreover, in
the safety and tolerability data there were no
cases of respiratory depression associated with
the use of FSLS.
The clinical trials of FSLS were designed to
evaluate safety and efficacy in treating
breakthrough cancer pain; all patients were
also taking concomitant opioids, such as
sustained-release morphine or transdermal
fentanyl, for their persistent cancer pain.
Therefore, the adverse events data reflect the
effects of study drug, but also reflect that this
was a population with active cancer causing
pain, taking ATC opioids and many other
medications.
Clinical Application of Sublingual Fentanyl
Fentanyl sublingual spray should only be
administered to adult patients already taking
at least 60 mg oral morphine per day or
equivalent alternative ATC opioid for a week
or longer [25]. Each FSLS carton contains
individual blister packages containing single
spray units of FSLS, a supply of small white
disposal bags for disposing of used FSLS units, a
medication guide, and a package insert. FSLS is
supplied in individually sealed blister packages
that should be opened with scissors
immediately before product use. The patient
should carefully spray the contents of the unit
into his or her mouth underneath the tongue.
The spray unit must be disposed of in used
unit dose systems immediately after use, and
any unneeded unit dose systems remaining
from a prescription as soon as they are no
longer needed. Consumed units represent a
special risk because they are no longer
protected by the child-resistant blister package,
yet may contain enough medicine to be fatal to
a child. A disposal bottle is provided with every
carton dispensed. This container is to be used by
patients or their caregivers to dispose of the
contents of any unneeded unit dose systems
when they are no longer needed.
Titration
Fentanyl sublingual spray should be individually
titrated to a dose that provides adequate
analgesia and minimizes side effects (Fig. 2;
Table 1). The initial dose of FSLS to treat
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episodes of breakthrough cancer pain is always
100 lg [25]. From this initial dose, the dose
should be titrated through steps of 200, 400,
600, 800, 1,200, and 1,600 lg to provide
adequate analgesia using a single FSLS dose per
breakthrough cancer pain episode with tolerable
side effects. For each breakthrough pain episode
treated, if pain is not relieved after 30 min,
patients may take one additional dose of the
same strength for that episode. Therefore, the
maximum of two doses of FSLS is recommended
for any breakthrough pain episode. Patients
should wait at least 4 h before treating another
episode of breakthrough pain with FSLS. FSLS is
not bioequivalent with other fentanyl products
and therefore patients should not be converted
on a microgram per microgram basis from other
fentanyl products.
Maintenance
Once titrated to a dose that provides adequate
pain relief and tolerable side effects, patients
should generally use one FSLS dose of the
appropriate strength per breakthrough pain
episode.
On those occasions when the breakthrough
pain episode is not relieved within 30 min after
administration of the FSLS dose, the patient may
take one additional dose using the same strength
for that episode. Patients should wait at least 4 h
before treating another episode of breakthrough
pain with FSLS. Once a successful dose has been
found, patients should limit consumption to four
or fewer doses per day. Dosage adjustment of FSLS
may be required in some patients in order to
continue to provide adequate relief of
breakthrough pain. If signs of excessive opioid
effects appear following administration of a single
FSLS dose, subsequent doses should be decreased.
Generally, only increase the FSLS dose when a
single administration of the current dose fails to
treat the breakthrough pain episode adequately
for several consecutive episodes. If the patient
experiences greater than four breakthrough pain
episodes per day, the dose of the maintenance
(ATC) opioid used for persistent pain should be
re-evaluated. In addition, if pain worsens,
re-evaluate the patient for changes in the
underlying pain condition.
Contraindications
Fentanyl sublingual spray is contraindicated in
opioid-naive patients, in the management of
acute or postoperative pain including headache/
migraine, and in patients with known
Fig. 2 Fentanyl sublingual spray titration process [23]
Table 1 Fentanyl sublingual spray titration steps [23]
FSLS dose (lg) Using (lg unit)
100 1 9 100
200 1 9 200
400 1 9 400
600 1 9 600
800 1 9 800
1,200 2 9 600
1,600 2 9 800
FSLS fentanyl sublingual spray
Pain Ther (2013) 2:1–9 7
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intolerance or hypersensitivity to any of its
components or the drug fentanyl.
Cost
When considering costs, the transmucosal
fentanyl preparations are usually compared to
oral opioids, the latter being considerably
cheaper. Although oral opioids may be helpful
for some breakthrough pains, particularly those
with a slow onset and long duration, they are
not suited to most of them [2]. The use of
transmucosal opioids is therefore based on an
assessment of the presenting breakthrough pain
and used when oral opioids are, or are likely to
be, ineffective. If there is any doubt, a
therapeutic trial of an oral opioid may help
before switching to the transmucosal route.
CONCLUSIONS
Breakthrough pain has been shown to occur
commonly in patients with cancer, and is often
of sudden onset, short duration, and is severe or
excruciating and short lasting, making
management difficult. The ideal treatment for
breakthrough pain should match the clinical and
dynamic profile of breakthrough pain. FSLS is
indicated for the management of breakthrough
pain in patients with cancer who are already
receiving opioid therapy for their background
cancer pain. The pharmacokinetic, efficacy,
tolerability and safety profile of FSLS suggest that
it has a valuable role to play in the symptomatic
pharmacological management of breakthrough
pain. The effective dose of FSLS is determined by
titration according to the needs of the individual
patient.
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